此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

PF-06821497 治疗复发/难治性 SCLC、去势抵抗性前列腺癌和滤泡性淋巴瘤

2026年11月9日 更新者:Pfizer

PF-06821497 治疗复发/难治性小细胞肺癌 (SCLC)、去势抵抗性前列腺癌 (CRPC) 和滤泡性淋巴瘤 (FL) 成年患者的 I 期剂量递增和扩展队列研究

The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.

Part 3, which is open for enrollment is seeking men who:

  • have Castration Resistant Prostate Cancer (CRPC) and
  • have previously received treatment for CRPC and have progressed from the last treatment

All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort).

In the assessment phase:

  • participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.
  • participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule.
  • participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule.

After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding.

The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.

研究概览

地位

招聘中

条件

干预/治疗

详细说明

This is an open label, multi center, Phase 1 dose escalation and dose expansion study of mevrometostat (PF-06821497) administered orally BID as a single agent or in combination with SOC to patients with CRPC, SCLC, and FL. The study consists of three parts (Part 1, Part 2, and Part 3) along with the Japan and China monotherapy cohorts. Part 1 and Part 2 are closed for enrollment. Part 1 tested monotherapy in 3 cohorts (Parts 1A, 1B, and 1C); Part 2 tested combination therapy in Parts 2A (dose escalation), 2B and 2C (does expansion).

Part 3 consists of the Bioequivalence (BE) and drug-drug interaction (DDI) substudies and are open for enrollment. The BE substudy will test between 2 mevrometostat formulation to confirm that they work in the body the same way. The DDI substudy will evaluate the effect of a strong CYP3A4 (an enzyme in your body that breaks down/ removes drugs) inhibitor on the PK of mevrometostat; a strong CYP3A4 inhibitor may slow down the breakdown/ removal of drugs in your body. The Sponsor may choose to delay or discontinue any cohorts or substudies.

研究类型

介入性

注册 (估计的)

453

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Guangdong
      • Guangzhou、Guangdong、中国、510120
        • 主动,不招人
        • The First Affiliated Hospital of Guangzhou Medical University
    • Hunan
      • Changsha、Hunan、中国、410013
        • 主动,不招人
        • Hunan Cancer Hospital
    • Jiangsu
      • Nanjing、Jiangsu、中国、210009
        • 主动,不招人
        • Zhongda Hospital Southeast University
      • Nanjing、Jiangsu、中国、210008
        • 主动,不招人
        • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
    • Sichuan
      • Chengdu、Sichuan、中国、610041
        • 招聘中
        • West China Hospital, Sichuan University
    • Zhejiang
      • Wenzhou、Zhejiang、中国、325000
        • 主动,不招人
        • The First Affiliated Hospital of Wenzhou Medical University
      • Moscow、俄罗斯、117186
        • 主动,不招人
        • LLC "Neyro-klinika"
      • Moscow、俄罗斯、125284
        • 终止
        • Moscow GBUZ "City clinical hospital n. a. S.P. Botkina" of Moscow health department
      • Moscow、俄罗斯、129301
        • 终止
        • SBHI of Moscow City Clinical Hospital
      • Omsk、俄罗斯、644013
        • 终止
        • Budgetary Healthcare Institution of Omsk region "Clinical Oncological Dispensary"
      • Saint Petersburg、俄罗斯、197341
        • 终止
        • Federal State Budgetary Institution National Medical Research Center n.a. V.A. Almazov
      • Saint Petersburg、俄罗斯、197758
        • 终止
        • Federal State Budgetary Institution National Medical Research Center for Oncology n.a. N.N.
      • Saint Petersburg、俄罗斯、198255
        • 终止
        • Saint Petersburg State Budgetary Healthcare Institution "City Clinical Oncological Dispensary"
      • Yaroslavl、俄罗斯、150054
        • 终止
        • State Budgetary Healthcare Institution of the Yaroslavl Region
    • Sankt-Peterburg
      • Pushkin、Sankt-Peterburg、俄罗斯、196603
        • 主动,不招人
        • Private Medical Institution "Euromedservice"
      • Haskovo、保加利亚、6300
        • 终止
        • Specialized Hospital for Active Treatment of Oncology - Haskovo
    • Chiba
      • Kashiwa、Chiba、日本、277-8577
        • 主动,不招人
        • National Cancer Center Hospital East
      • Bydgoszcz、波兰、85-048
        • 尚未招聘
        • In-Vivo Sp. z o.o. In-vivo Bydgoszcz
      • Koszalin、波兰、75-581
        • 主动,不招人
        • Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie
      • Krakow、波兰、30-348
        • 招聘中
        • Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
      • Rzeszów、波兰、35-326
        • 主动,不招人
        • Centrum Medyczne MEDYK
      • Warsaw、波兰、02-781
        • 主动,不招人
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
    • Arizona
      • Tucson、Arizona、美国、85719
        • 主动,不招人
        • Banner-University Medical Center Tucson
      • Tucson、Arizona、美国、85719
        • 主动,不招人
        • The University of Arizona Cancer Center-North Campus
      • Tucson、Arizona、美国、85724
        • 主动,不招人
        • The University of Arizona Cancer Center
      • Tucson、Arizona、美国、85741
        • 终止
        • Arizona Urology Specialists, PLLC
    • California
      • Anaheim、California、美国、92801
        • 主动,不招人
        • Pacific Cancer Medical Center INC
      • Duarte、California、美国、91010
        • 主动,不招人
        • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
      • Duarte、California、美国、91010
        • 主动,不招人
        • City of Hope Investigational Drug Services (IDS)
    • Connecticut
      • Norwalk、Connecticut、美国、06856
        • 主动,不招人
        • Norwalk Hospital
    • Kansas
      • Fairway、Kansas、美国、66205
        • 主动,不招人
        • The University of Kansas Cancer Center, Investigational Drug Services
      • Fairway、Kansas、美国、66205
        • 主动,不招人
        • The University of Kansas Clinical Research Center
      • Kansas City、Kansas、美国、66160
        • 主动,不招人
        • The University of Kansas Hospital
      • Kansas City、Kansas、美国、66160
        • 主动,不招人
        • The University of Kansas Medical Center Medical Office Building
      • Overland Park、Kansas、美国、66211
        • 主动,不招人
        • The University of Kansas Cancer Center - Indian Creek Campus
      • Westwood、Kansas、美国、66205
        • 主动,不招人
        • The University of Kansas Cancer Center
    • Kentucky
      • Louisville、Kentucky、美国、40202
        • 主动,不招人
        • Norton Cancer Institute, Norton Healthcare Pavilion
      • Louisville、Kentucky、美国、40202
        • 主动,不招人
        • Norton Hospital
      • Louisville、Kentucky、美国、40202
        • 主动,不招人
        • Norton Cancer Institute - Downtown
    • Maryland
      • Rockville、Maryland、美国、20850
        • 终止
        • Maryland Oncology Hematology, P.A.
    • Massachusetts
      • Boston、Massachusetts、美国、02215
        • 主动,不招人
        • Dana-Farber Cancer Institute
      • Boston、Massachusetts、美国、02115
        • 主动,不招人
        • Brigham and Women's Hospital
      • Newton、Massachusetts、美国、02459
        • 主动,不招人
        • Dana Farber Cancer Institute- Chestnut Hill
    • Nebraska
      • Omaha、Nebraska、美国、68130
        • 招聘中
        • Oncology Hematology West, PC dba Nebraska Cancer Specialists
    • New Jersey
      • Hackensack、New Jersey、美国、07601
        • 主动,不招人
        • Hackensack University Medical Center
      • Hackensack、New Jersey、美国、07601
        • 主动,不招人
        • John Theurer Cancer Center at Hackensack University Medical Center
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73104
        • 招聘中
        • OU Health University of Oklahoma Medical Center
      • Oklahoma City、Oklahoma、美国、73104
        • 招聘中
        • Stephenson Cancer Center (chemo location)
    • South Carolina
      • Myrtle Beach、South Carolina、美国、29572
        • 招聘中
        • Carolina Urologic Research Center
      • Myrtle Beach、South Carolina、美国、29572
        • 招聘中
        • Parkway Surgery Center
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • 招聘中
        • Sarah Cannon Research Institute - Pharmacy
      • Nashville、Tennessee、美国、37203
        • 招聘中
        • SCRI Oncology Partners
    • Texas
      • Austin、Texas、美国、78705
        • 终止
        • Texas Oncology - Austin Midtown
      • Dallas、Texas、美国、75390
        • 主动,不招人
        • UT Southwestern Medical Center
      • Dallas、Texas、美国、75390
        • 主动,不招人
        • University of Texas Southwestern Medical Center - Simmons Cancer Center
      • Dallas、Texas、美国、75390
        • 主动,不招人
        • UT Southwestern University Hospital - William P. Clements, Jr
      • Dallas、Texas、美国、75390
        • 主动,不招人
        • UT Southwestern University Hospital - Zale Lipshy
      • Irving、Texas、美国、75063
        • 终止
        • US Oncology Investigational Product Center (IPC)
      • Irving、Texas、美国、75063
        • 终止
        • US Oncology Investigational Products Center
      • Irving、Texas、美国、75039
        • 招聘中
        • NEXT Dallas
      • San Antonio、Texas、美国、78229
        • 招聘中
        • NEXT Oncology
    • Virginia
      • Fairfax、Virginia、美国、22031
        • 主动,不招人
        • Virginia Cancer Specialists, PC
    • Washington
      • Port Angeles、Washington、美国、98362
        • 主动,不招人
        • Olympic Medical Center
      • Poulsbo、Washington、美国、98370
        • 主动,不招人
        • Fred Hutchinson Cancer Center Alliance Peninsula
      • Seattle、Washington、美国、98195
        • 主动,不招人
        • University of Washington Medical Center
      • Seattle、Washington、美国、98109
        • 主动,不招人
        • Fred Hutchinson Cancer Center
      • Barcelona、西班牙、08035
        • 招聘中
        • Hospital Universitari Vall d'Hebron
      • Barcelona、西班牙、08036
        • 招聘中
        • Hospital Clinic de Barcelona
      • Barcelona、西班牙、08023
        • 招聘中
        • Hospital Quironsalud Barcelona
      • Madrid、西班牙、28034
        • 招聘中
        • Hospital Universitario Ramon y Cajal
      • Madrid、西班牙、28050
        • 招聘中
        • Hospital Universitario HM Sanchinarro
      • Madrid、西班牙、28040
        • 招聘中
        • H.U. Fundación Jiménez Díaz
      • Madrid、西班牙、28041
        • 招聘中
        • Hospital Universitario 12 De Octubre
      • Málaga、西班牙、29010
        • 招聘中
        • Hospital Universitario Virgen de la Victoria
      • Valencia、西班牙、46026
        • 主动,不招人
        • Hospital Universitari i Politecnic La Fe
    • Barecelona
      • L'Hospitalet de Llobregat、Barecelona、西班牙、08908
        • 主动,不招人
        • Institut Català d´Oncología (ICO)-H. Durán i Reynals
    • Castellon
      • Castellon、Castellon、西班牙、12002
        • 主动,不招人
        • Consorcio Hospitalario Provincial de Castellon
    • Madrid
      • Pozuelo de Alarcón、Madrid、西班牙、28223
        • 招聘中
        • Hospital Quironsalud Madrid
    • Madrid, Comunidad de
      • Madrid、Madrid, Comunidad de、西班牙、28040
        • 招聘中
        • Hospital Clinico San Carlos
    • Kyǒnggi-do
      • Seongnam、Kyǒnggi-do、韩国、13620
        • 招聘中
        • Seoul National University Bundang Hospital
    • Seoul-teukbyeolsi [seoul]
      • Seoul、Seoul-teukbyeolsi [seoul]、韩国、03080
        • 主动,不招人
        • Seoul National University Hospital
      • Seoul、Seoul-teukbyeolsi [seoul]、韩国、07985
        • 主动,不招人
        • Ewha Womans University Mokdong Hospital
      • Seoul、Seoul-teukbyeolsi [seoul]、韩国、03722
        • 主动,不招人
        • Severance Hospital, Yonsei University Health System
    • Taejǒn-kwangyǒkshi
      • Daejeon、Taejǒn-kwangyǒkshi、韩国、35015
        • 主动,不招人
        • Chungnam national university hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Part 1 and Part 2 (Closed for enrollment).

Part 3 Key Inclusion Criteria:

  • Histological or cytological diagnosis of castration resistant prostate cancer.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.
  • Adequate bone marrow, renal, and liver function

Part 3 Key Exclusion Criteria:

  • Prior irradiation to >25% of the bone marrow.
  • QTcF interval >480 msec at screening.
  • Hypertension that cannot be controlled by medications (>150/90 mmHg despite optimal medical therapy).
  • Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)
  • Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
  • Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4/5 inducers or inhibitors
  • Prior enzalutamide within the last 4 weeks
  • DDI SUBSTUDY:
  • history of CHF or evidence of ventricular dysfunction
  • fructose intolerance
  • coadministration of CYP3A4 substrates
  • Any history of prior malignancies, except for carcinoma in situ or non-melanoma skin cancer, prior non-hematologic malignancies >= 3 years before randomization with no subsequent recurrence or progression, Stage 0 or 1 non-hematologic cancer < 3 years before randomization that has a remote probability of recurrence or progression.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Dose Escalation (Part 1A)

Participants with SCLC, CRPC and FL will receive mevrometostat at escalating dose levels

Oral continuous

其他名称:
  • EZH2i
实验性的:Dose Escalation (Part 1B)

Participants with FL will receive mevrometostat at escalating dose levels

Oral continuous

其他名称:
  • EZH2i
实验性的:Dose Escalation (Part 1C)

Participants with mCRPC will receive mevrometostat at escalating dose levels.

Oral continuous

其他名称:
  • EZH2i
实验性的:Dose Escalation (Part 2A)

Participants with mCRPC and SCLC will receive mevrometostat at escalating dose levels in combination with SOC.

Oral continuous

其他名称:
  • EZH2i

Oral continuous

其他名称:
  • 新坦迪
实验性的:Dose Expansion (Part 2B)

Participants with CRPC will receive mevrometostat in combination with SOC or SOC alone.

Oral continuous

其他名称:
  • EZH2i

Oral continuous

其他名称:
  • 新坦迪
实验性的:Japan Cohort

Participants with CRPC will receive mevrometostat at one or two doses

Oral continuous

其他名称:
  • EZH2i
实验性的:China cohort

Participants will receive mevrometostat at one or two doses

Oral continuous

其他名称:
  • EZH2i
实验性的:Dose Expansion (Part 2C)

Participants with mCRPC will receive mevrometostat at a different dose/dosing regimen than that of Part 2B in combination with SOC

Oral continuous

其他名称:
  • EZH2i

Oral continuous

其他名称:
  • 新坦迪
实验性的:BE Substudy

In the assessment phase, each enrolled participant will receive single doses of the 2 different mevrometostat formulations in 3 periods with alternating dosing and washout between each dose. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day.

Oral continuous

其他名称:
  • EZH2i

Oral continuous

其他名称:
  • 新坦迪
实验性的:DDI Substudy

The DDI substudy assessment phase will consist of 2 Cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (combination cohort). In the Cohort 1 assessment phase, each enrolled participant will receive a combination of mevrometostat and itraconazole based on preset schedule. In the Cohort 2 assessment phase, each enrolled participant will receive a combination of mevrometostat, enzalutamide, and itraconazole based on preset schedule. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day.

Oral continuous

其他名称:
  • EZH2i

Oral continuous

其他名称:
  • 新坦迪

Oral solution

其他名称:
  • 斯皮仁诺
  • 托苏拉
  • 翁梅尔

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
大体时间:Baseline up to 90 days

First cycle DLTs will be utilized to determine the MTD

Baseline up to 90 days
Overall safety profile including adverse events
大体时间:Baseline up to approximately 2 years

Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version [4.03])

Baseline up to approximately 2 years
Preliminary efficacy determination as evaluated by disease specific response criteria
大体时间:Through study completion, approximately 2 years past last patient first visit.

Objective response using Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC). Progression-free survival in Part 2B in patients with CRPC.

Through study completion, approximately 2 years past last patient first visit.
Overall safety profile including laboratory abnormalities
大体时间:Baseline up to approximately 2 years

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version [4.03]), and timing.

Baseline up to approximately 2 years
Overall safety profile including vital signs
大体时间:Baseline up to approximately 2 years

Vital sign changes from baseline including blood pressure, heart rate, ECG changes.

Baseline up to approximately 2 years
Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival
大体时间:Baseline until disease progression or death or through study completion (approx 2 years)

PCWG3

Baseline until disease progression or death or through study completion (approx 2 years)

次要结果测量

结果测量
措施说明
大体时间
Evaluate time to event anti-tumor activity of mevrometostat including progression-free survival (PFS), PSA50, Duration of Response (DoR), Time to first skeletal related event and Time to symptomatic skeletal related event, depending on tumor type.
大体时间:Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.

Time to event endpoints based on Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC)

Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
Evaluate overall survival
大体时间:Baseline up to approximately 2 years

Median time to death proportion of patients alive at 6 months, 1 year, and 2 years.

Baseline up to approximately 2 years
Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)
大体时间:At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)
大体时间:At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Area Under the Curve (AUC)
大体时间:At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)
大体时间:At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)
大体时间:At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)
大体时间:At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Singe dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Evaluate the impact of mevrometostat on patient reported outcomes.
大体时间:At specific time-points from Cycle 1 Day 1 to End of Treatment visit.

Quality of Life and Time to Functional Status Deterioration as assessed by FACT-P.

At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
Impact of mevrometostat in combination with enzalutamide, enzalutamide alone and mevrometostat alone on symptoms and symptomatic toxicity
大体时间:At specific time points from Cycle1 Day 1 to end of treatment

Questionnaire customized from PRO-CTCAE.

At specific time points from Cycle1 Day 1 to end of treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Pfizer CT.gov Call Center、Pfizer

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2018年4月17日

初级完成 (估计的)

2028年4月20日

研究完成 (估计的)

2029年7月7日

研究注册日期

首次提交

2018年2月12日

首先提交符合 QC 标准的

2018年3月2日

首次发布 (实际的)

2018年3月9日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • C2321001
  • 2023-509179-18-00 (注册表标识符:CTIS (EU))
  • EZH2 (其他标识符:Alias Study Number)
  • 2023 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.